These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 10951150

  • 21. Effects of topically applied rapamycin and mycophenolic acid on TNCB-induced atopic dermatitis-like skin lesions in NC/Nga mice.
    Jung KE, Lee YJ, Ryu YH, Kim JE, Kim HS, Kim BJ, Kang H, Park YM.
    Int Immunopharmacol; 2015 Jun; 26(2):432-8. PubMed ID: 25794646
    [Abstract] [Full Text] [Related]

  • 22. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
    Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, Tang CS, Chan TM.
    Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
    [Abstract] [Full Text] [Related]

  • 23. A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy.
    Farrell AM, Antrobus P, Simpson D, Powell S, Chapel HM, Ferry BL.
    Br J Dermatol; 2001 Jan; 144(1):24-33. PubMed ID: 11167679
    [Abstract] [Full Text] [Related]

  • 24. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May 27; 345(8961):1321-5. PubMed ID: 7752752
    [Abstract] [Full Text] [Related]

  • 25. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD.
    J Clin Gastroenterol; 2005 Feb 27; 39(2):168-71. PubMed ID: 15681915
    [Abstract] [Full Text] [Related]

  • 26. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
    Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D'Cruz DP, Abbs IC, Khamasta MA, Hughes GR.
    J Rheumatol; 2005 Jun 27; 32(6):1047-52. PubMed ID: 15940766
    [Abstract] [Full Text] [Related]

  • 27. Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome : a pilot study.
    Brunetti L, Francavilla R, Tesse R, Fiermonte P, Dambra P, Massagli M, Loria MP, Armenio L.
    BioDrugs; 2005 Jun 27; 19(6):393-9. PubMed ID: 16392891
    [Abstract] [Full Text] [Related]

  • 28. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181
    [Abstract] [Full Text] [Related]

  • 29. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease.
    Larkin G, Lightman S.
    Ophthalmology; 1999 Feb 15; 106(2):370-4. PubMed ID: 9951492
    [Abstract] [Full Text] [Related]

  • 30. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar 15; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 31. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres.
    Garritsen FM, Roekevisch E, van der Schaft J, Deinum J, Spuls PI, de Bruin-Weller MS.
    J Eur Acad Dermatol Venereol; 2015 Oct 15; 29(10):1905-12. PubMed ID: 25752497
    [Abstract] [Full Text] [Related]

  • 32. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.
    Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, Nzeusseu Toukap A, Depresseux G, Houssiau FA.
    Clin Exp Rheumatol; 2007 Oct 15; 25(2):287-92. PubMed ID: 17543155
    [Abstract] [Full Text] [Related]

  • 33. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation.
    von Vietinghoff S, Koltsova EK, Mestas J, Diehl CJ, Witztum JL, Ley K.
    J Am Coll Cardiol; 2011 May 24; 57(21):2194-204. PubMed ID: 21596236
    [Abstract] [Full Text] [Related]

  • 34. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis.
    Phan K, Smith SD.
    J Dermatolog Treat; 2020 Dec 24; 31(8):810-814. PubMed ID: 31294617
    [Abstract] [Full Text] [Related]

  • 35. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 36. Mycophenolate mofetil for the treatment of chronic dermatitis: an open-label study of 16 patients.
    Jackson JM, Fowler JF, Callen JP, Lorenz DJ.
    J Drugs Dermatol; 2010 Apr 27; 9(4):356-62. PubMed ID: 20514793
    [Abstract] [Full Text] [Related]

  • 37. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
    Laftavi MR, Hai F, Laftavi H, Feng L, Said M, Patel S, Kohli R, Alnimri M, Dayton M, Pankewycz O.
    Transplant Proc; 2011 Mar 27; 43(2):478-81. PubMed ID: 21440738
    [Abstract] [Full Text] [Related]

  • 38. Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil.
    Hantash B, Fiorentino D.
    Arch Dermatol; 2006 Jan 27; 142(1):109-10. PubMed ID: 16415398
    [No Abstract] [Full Text] [Related]

  • 39. Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children.
    Trachtman H, Christen E, Frank R, Rini J, Palestro C, Perelstein E, Weiss L, Tarapore F, Fortune S, Horowitz J.
    Am J Kidney Dis; 2008 Oct 27; 52(4):706-15. PubMed ID: 18554762
    [Abstract] [Full Text] [Related]

  • 40. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
    Karim MY, Pisoni CN, Ferro L, Tungekar MF, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR.
    Rheumatology (Oxford); 2005 Oct 27; 44(10):1317-21. PubMed ID: 16049051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.